madman
Super Moderator
Jun 03, 2020 07:00 am
TORONTO --
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that, as of July 1, 2020, Express Scripts, Inc., one of the leading pharmacy benefit managers (PBMs) in the United States, has elected to make NATESTO® (testosterone nasal gel) a preferred brand on its National Preferred Drug List.
"This formulary placement by Express Scripts is a significant milestone in Acerus’ commercial efforts in the United States,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “Within 10 weeks of the implementation of Acerus’ market access efforts, NATESTO® has been added as Preferred on the Express Scripts National Preferred formulary. We believe this improved coverage will enhance patient access and increase physician’s prescribing of NATESTO® for the more than 13 million U.S. men diagnosed with hypogonadism."
Express Scripts serves more than 3,000 clients covering 70 million lives, including approximately 9 million lives managed by Cigna HealthCare. Drugs listed on formulary as preferred brands have been evaluated by the pharmacy benefit manager from a therapeutic and value perspective. Preferred brand drugs may be available to patients at a lower co-pay or co-insurance than non-preferred brand drugs.
Acerus Announces Significant Improvement in NATESTO® Insurance Coverage in the United States
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription p
www.businesswire.com
TORONTO --
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that, as of July 1, 2020, Express Scripts, Inc., one of the leading pharmacy benefit managers (PBMs) in the United States, has elected to make NATESTO® (testosterone nasal gel) a preferred brand on its National Preferred Drug List.
"This formulary placement by Express Scripts is a significant milestone in Acerus’ commercial efforts in the United States,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “Within 10 weeks of the implementation of Acerus’ market access efforts, NATESTO® has been added as Preferred on the Express Scripts National Preferred formulary. We believe this improved coverage will enhance patient access and increase physician’s prescribing of NATESTO® for the more than 13 million U.S. men diagnosed with hypogonadism."
Express Scripts serves more than 3,000 clients covering 70 million lives, including approximately 9 million lives managed by Cigna HealthCare. Drugs listed on formulary as preferred brands have been evaluated by the pharmacy benefit manager from a therapeutic and value perspective. Preferred brand drugs may be available to patients at a lower co-pay or co-insurance than non-preferred brand drugs.
